… Tau monomers and oligomers stimulated NLRP3 activation, but tau fibrils did not. In … by
activating NLRP3, indicating that the NLRP3 inflammasome may be a potential therapeutic target …

… therapeutic targets and innovative agents must be developed. Notably, the NLRP3 inflammasome
… assembly, the NLRP3 inflammasome is persistently activated during the pathogenesis …

… of NLRP3 inflammasome activation, how dysregulation of NLRP3 inflammasome activation
causes disease, and potential therapeutics that inhibit NLRP3 inflammasome activation. …

… This study further showed that NLRP3 inflammasome activation is caused by the action of
cathepsin B released from the lysosome rather than the direct actions of Aβ. These findings …

… Moreover, focusing on the NLRP3 inflammasome and combining with the upstream and …
of NLRP3 inflammasome as targets, we review the pharmacologically related targets and …

… in clinical studies, supporting this therapeutic approach. In this review, we discuss the
activation, biological functions, and treatment targeting the NLRP3 inflammasome in the context of …

… infection, the NLRP3 inflammasome appears to be a potential drug target in the treatment of
… This manuscript highlights the importance of NLRP3 inflammasome in the pathogenesis of …

… the NLRP3 inflammasome in mild TBI, how factors such as biological sex may affect NLRP3
… the exciting potential of the NLRP3 inflammasome as a target for treatments and biomarkers …

… and glia cell activation in SCDH. This study indicates that NLRP3 inflammasome may be
a novel therapeutic target for CRPS-I management. NLRP3 in central neuropathic pain (CNP) …

… Importantly, the NLRP3 inflammasome might be a therapeutic target for preventing preterm
… activate the NLRP3 inflammasome in fetal membranes, increase the levels of the NLRP3 …